Company

Osteal Therapeutics, Inc.

Texas-based biopharmaceutical developer of targeted therapies for musculoskeletal infections, led by its VT-X7 product.

About

Founded in 2013 and based in Texas, US, Osteal Therapeutics, Inc. develops medicines for musculoskeletal infections, with its primary product VT-X7 aimed at periprosthetic joint infections of the hip and knee. Its APEX-2 clinical trial compares its procedure's performance with two-stage surgery. Co-founders Jude Paganelli and Brian de Beaubin work alongside CEO David Thompson. In June 2024 it raised USD 50 million in Series D funding led by Zimmer Biomet Holdings, Inc., valuing the company at USD 231.79 million post-money.

4Funding rounds

5Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in